Grip device width setting value

General Details:

Name:
Grip device width setting value
Steward:
NINDS
Definition:
Value of the width setting on the grip device used to test the participant/subject's grip strength
Registration Status:
Qualified

Permissible Values:

Data Type:
Number
Unit of Measure:
Ids:
Value Code Name Code Code System Code Description

Designations:

Designation:
Grip device width setting value
Tags:

Designations:

Definition:
Value of the width setting on the grip device used to test the participant/subject's grip strength
Tags:

Reference Documents:

ID:
Title:
URI:
Provider Org:
Language Code:
Document:
Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, Watson ML, Mahoney K, Chen M, Saikali K, Mao J, Russell AJ, Hansen RL, Malik F, Wolff AA; Neals/Cytokinetics Study Team. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13(5):430–438.
ID:
Title:
URI:
Provider Org:
Language Code:
Document:
Shefner J, Cudkowicz ME, Maragakis N, Cedarbaum JM, Lee J, Jones D, Watson ML, Shaver K, Chen M, Saikali K, Mao J, Russell AK, Hansen L, Malik F, Wolff AA, for the NEALS/Cytokinetics Study Team. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in Amyotrophic Lateral Sclerosis. (submitted for publication)
ID:
Title:
URI:
Provider Org:
Language Code:
Document:
Personius, K. E., S. Pandya, et al. (1994). "Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group." Phys Ther 74(3): 253-263.<br /><br />Kissel, J. T., M. P. McDermott, et al. (2001). "Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy." Neurology 57(8): 1434-1440.<br /><br />Wagner, K. R., J. L. Fleckenstein, et al. (2008). "A phase I/Iitrial of MYO-029 in adult subjects with muscular dystrophy." Ann Neurol 63(5): 561-571.<br /><br />van der Kooi, E. L., O. J. Vogels, et al. (2004). "Strength training and albuterol in facioscapulohumeral muscular dystrophy." Neurology 63(4): 702-708.<br /><br />Cooper R, Kuh D, Hardy R. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. BMJ. 2010;341:c4467. E<br /><br />Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. The journals of gerontology Series A, Biological sciences and medical sciences. 2006;61(1):72-77.

Identifiers:

Source:
NLM
Id:
N9n19PsNzsY
Version:
3.1
Source:
NINDS
Id:
C10854
Version:
3
Source:
BRICS Variable Name
Id:
GripDeviceWidthSettingVal
Version: